FindTrial
Sign In

Busulfan (conditioning for ALLO Transplant)

DRUG2 trials

Sponsors

Massachusetts General Hospital, University of Illinois at Chicago

Conditions

Acute Myeloid Leukemia RefractoryAcute Myeloid Leukemia, Relapsed, AdultChronic Lymphocytic LeukemiaChronic Myeloid Leukemia - Accelerated PhaseDiffuse, Large B-Cell, LymphomaHodgkin's LymphomaLymphoma, Low-GradeLymphoma, Small Lymphocytic

Phase 2

Tandem Auto-Allo Transplant for Lymphoma
CompletedNCT01181271
Massachusetts General HospitalChronic Lymphocytic Leukemia, Diffuse, Large B-Cell, Lymphoma, Hodgkin's Lymphoma +4
Start: 2010-08-31End: 2016-02-29Updated: 2017-03-09
Intensity Modulated Total Marrow Irradiation in Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA Mismatched Allogeneic Transplantation Patients With High-Risk Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), and Myelodysplastic Syndrome (MDS)
RecruitingNCT06802315
University of Illinois at ChicagoAcute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, Relapsed, Adult, Chronic Myeloid Leukemia - Accelerated Phase +1
Start: 2025-02-04End: 2032-03-31Target: 38Updated: 2025-06-25